AERIE PHARMACEUTICALS, INC.
FORT WORTH, TX

We commenced our Mercury 3 trial for European approval in mid-2017. Mercury 3 is designed to compare Roclatan™ to Ganfort®, a fixed-dose combination product of bimatoprost and timolol marketed in Europe, which if successful, is expected to improve our commercialization prospects in that region. Based on its Phase 2b and Phase 3 registration trial performance, we believe Roclatan™ ophthalmic solution has the potential to be the most efficacious therapy in the market for patients with glaucoma or ocular hypertension. In addition to our primary product candidates, Rhopressa® ophthalmic solution and Roclatan™ ophthalmic solution, we are also exploring the longer-term impact of Rhopressa® ophthalmic solution on the diseased trabecular meshwork, its ability to lower IOP consistently over a 24-hour period, and also evaluating possible uses of our existing proprietary portfolio of Rho kinase inhibitors beyond glaucoma. We have issued several research updates on preclinical results demonstrating the potential for Rhopressa® ophthalmic solution to have disease-modifying activity in glaucoma patients by stopping and potentially reversing fibrosis in the trabecular meshwork, and also increasing perfusion in the trabecular outflow pathway thus increasing both drainage and the delivery of nutrients to the diseased tissue. We are also evaluating in preclinical studies AR-13503, an Aerie-owned small molecule that inhibits both Rho kinase and protein kinase C. AR-13503 has demonstrated significant reduction in lesion size associated with wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in animal models. In addition, our preclinical retina franchise also includes AR-1105, a dexamethasone steroid with the potential to treat DME. Further, we are exploring drug delivery opportunities using a bio-erodible polymer sourced from DSM that may provide sustained release of small molecule product candidates such as AR-13503 to the retina. We also have exclusive rights to PRINT® technology for ophthalmic indications, thus providing a manufacturing platform for precisely-sized implants. We own the worldwide rights for our current product candidates and retain the right to seek approval for all indications for these products. We currently plan to commercialize our products ourselves in North America. Regarding our international commercialization strategy, if our product candidates are successful, we plan to commercialize ourselves in Europe, and likely with a partner in Japan. Our intellectual property portfolio contains patents and pending patent applications related to composition of matter, pharmaceutical compositions and methods of use for our product candidates. We have patent protection for our primary product candidates, Rhopressa® ophthalmic solution and Roclatan™ ophthalmic solution, in the United States through at least 2030. Key Product-Related Milestones You can contact Aerie Pharmaceuticals’ Board of Directors to provide comments, to report concerns, or to ask a question, at the following address. Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Aerie Pharmaceuticals board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as: Product complaints